Recent Updates — NEO
NeoGenomics reported third-quarter 2026 total revenue of $209 million, an 11% increase year-over-year, driven by a 13% rise in clinical services revenue. Adjusted EBITDA expanded to $19 million, up from $12 million in the prior-year period, while GAAP net loss narrowed to $8 million. The company raised its full-year 2026 adjusted EBITDA guidance to approximately $60 million and updated its revenue outlook. Additionally, NeoGenomics announced a leadership succession plan effective January 4, 2027, with President and COO Warren Stone becoming CEO and current CEO Tony Zook transitioning to Executive Chairman. NeoGenomics is a leading provider of oncology diagnostic solutions that enable precision medicine.
NeoGenomics appointed President and COO Warren Stone as Chief Executive Officer and Board member, effective January 4, 2027. Current CEO Tony Zook will transition to Executive Chairman at the same time. The Board also increased its size from ten to eleven directors, appointed Michael Kelly as Lead Independent Director, and noted that Chair Lynn Tetrault will step down as Chair but remain a director until the 2027 Annual Meeting, where she does not intend to stand for reelection. Concurrently, the company announced preliminary unaudited third quarter revenue of approximately $209 million, reflecting next-generation sequencing revenue growth of about 28%. NeoGenomics operates in the oncology diagnostics industry, providing cancer genetics testing and information services.
NeoGenomics, Inc. announced that Alicia Olivo, Executive Vice President, General Counsel and Business Development, will transition from her role and cease serving as General Counsel effective September 21, 2026. Ms. Olivo will remain an employee until October 2, 2026 for transitional purposes and is eligible for separation payments consistent with her employment agreement. This executive departure represents a material change in key leadership. NeoGenomics operates in the healthcare industry, providing molecular diagnostic testing services.
NeoGenomics, Inc. reported second-quarter 2026 results with total revenue increasing 11% year-over-year to $202 million, driven by a 14% rise in clinical revenue and 26% growth in next-generation sequencing. The company recorded GAAP net income of $2 million, including an $11 million gain on debt extinguishment, and delivered adjusted EBITDA of $14 million, up 36%. NeoGenomics raised its full-year 2026 revenue guidance to a range of $802–$806 million and adjusted EBITDA guidance to $56–$58 million. The quarter also saw the completion of a $316 million private offering of 0.75% convertible senior notes due 2032, used to repurchase approximately $276 million of existing convertible notes and $25 million in common stock. NeoGenomics operates in the healthcare diagnostics industry, providing oncology testing and precision medicine solutions.
NeoGenomics, Inc. finalized a civil settlement with the U.S. Department of Justice on July 20, 2026, to resolve an investigation into consulting and service agreements regarding federal healthcare laws. The company agreed to pay $9,813,260 to resolve the matter, which was previously addressed via a $11.2 million reserve accrued as of March 31, 2026. The settlement does not constitute an admission of liability. NeoGenomics, Inc. is a healthcare company providing precision oncology diagnostics.
NeoGenomics, Inc. finalized a civil settlement with the U.S. Department of Justice to resolve an investigation into consulting services provided to healthcare providers. The company agreed to pay $9,813,260 plus 4.250% annual interest from January 16, 2026, to resolve the matter, utilizing a previously accrued reserve of $11.2 million. NeoGenomics is a cancer diagnostics company specializing in cancer genetics testing and information services.